M.D., Ph.D. Professor Akifumi Takaori-Kondo
Hematology is one of the areas in which active interactions and mutual stimulations between clinical medicine and basic science have been producing remarkable progress. We are trying to obtain deeper insights into mechanisms of and develop effective treatments for various hematological diseases, with a motto, “from bedside to bench, from bench to bedside”.
Research and Education
We perform our research, focusing on “cure” of hematological malignancies and infectious diseases, by bidirectional approaches, that is, from bedside to bench, and from bench to bedside. Our research extends over both basic science and clinical medicine in hematology, immunology and virology, and covers diverse fields as follows: 1) basic and clinical research on the pathophysiology and the treatment of hematological malignancies including leukemia, MDS, lymphoma, myeloma and ATL, 2) basic and clinical research on oncogenic mechanisms mediated by APOBEC3-induced genome mutagenesis and the impaired DNA repair systems in cancer cells, 3) application of iPS cell technology to basic and clinical research on hematological disorders and regenerative medicine of the blood, 4) basic and clinical research on the pathophysiology of infectious diseases including HIV, and host defense against them, 5) basic and clinical research on dendritic cells and tumor immunotherapy, and 6) basic and clinical research on hematopoietic stem cell transplantation and cellular immunotherapy (CAR T-cell therapy, etc.). By these, we aim to elucidate the pathophysiology of hematological malignancies and infectious diseases, thereby develop novel diagnostics and therapeutic strategies, and apply them to clinical practice.
Department members （April, 2022）
Recent Publications
- Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada TA, Kaneda A, Nakagawa S, Sato K and Genotype to Phenotype Japan C. Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum. N Engl J Med. 385: 2397-2399, 2021.
- Iwasaki M, Kanda J, Arai Y, Kondo T, Ishikawa T, Ueda Y, Imada K, Akasaka T, Yonezawa A, Yago K, Nohgawa M, Anzai N, Moriguchi T, Kitano T, Itoh M, Arima N, Takeoka T, Watanabe M, Hirata H, Asagoe K, Miyatsuka I, An LM, Miyanishi M and Takaori-Kondo A. Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning. Blood Adv. 6: 2618-2627, 2022.
- Muranushi H, Shindo T, Chen-Yoshikawa TF, Yoshizawa A, Ngo HT, Gochi F, Date H and Takaori-Kondo A. Dual inhibition of the MEK/ERK and PI3K/AKT pathways prevents pulmonary GVHD suppressing perivenulitis and bronchiolitis. Blood Adv.
- Yuan H, Nishikori M, Otsuka Y, Arima H, Kitawaki T and Takaori-Kondo A. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment. Cancer Sci. 112: 4604-4616, 2021.
- Kazuma Y, Shirakawa K, Tashiro Y, Yamazaki H, Nomura R, Horisawa Y, Takeuchi S, Stanford E, Konishi Y, Matsui H, Matsumoto T, Tanabe F, Morishita R, Ito S and Takaori-Kondo A. ILF2 enhances the DNA cytosine deaminase activity of tumor mutator APOBEC3B in multiple myeloma cells. Sci Rep. 12: 2278, 2022.
Laboratory
M.D., Ph.D. Professor: Akifumi Takaori-Kondo
Associate Professor: Kouhei Yamashita
Senior Lecturer: Momoko Nishikori
Senior Lecturer: Junya Kanda
Assistant Professor: Toshio Kitawaki
Assistant Professor: Takero Shindo
Assistant Professor: Kotaro Shirakawa
Assistant Professor: Takashi Sakamoto
Assistant Professor: Hiroshi Arima
Assistant Professor: Chisaki Mizumoto
Assistant Professor: Kazuhisa Chonabayashi
Assistant Professor: Kenichi Ishiyama
Assistant Professor: Yasuyuki Arai (Department of Transfusion and Cell Therapy)
Assistant Professor: Tomoyasu Jo (Department of Transfusion and Cell Therapy)
TEL：+81-75-751-4964
FAX：+81-75-751-4963
e-mail：hemato@kuhp.kyoto-u.ac.jp
URL：https://hematol.kuhp.kyoto-u.ac.jp/index.html